Key facts
- This page summarizes Jane Pritchett Henderson's Form 4 filing for Sesen Bio, Inc. (CARM).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 10 May 2021, 20:45.
Jane Pritchett Henderson - 03 May 2021 Form 4 Insider Report for Sesen Bio, Inc. (CARM)
- Reporting relationship
- Director
- Issuer ticker
- CARM
- Reported as of
- 03 May 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 May 2021, 20:45:34 UTC
- Next SEC filing
- 20 May 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Monica Forbes, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jane Pritchett Henderson filed Form 4 for Sesen Bio, Inc. (CARM) on 10 May 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CARM
transaction
Derivative
Stock Option
Award
- Transaction value
- $0
- Shares
- +92,500
- Change %
- Price
- $0.000000
- Shares after
- 92,500
- Date
- 03 May 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 92,500
- Exercise price
- $2.79
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option was granted on May 3, 2021 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. In April 2021, Sesen Bio, Inc.'s compensation committee, based on market analysis by Radford, recommended to the Sesen Bio, Inc. board of directors, and the board of directors approved, an increase in non-employee director equity compensation from the 50th percentile to the 75th percentile of the Radford market analysis of public, pre-commercial biopharmaceutical companies with less than 200 employees and market values between $250 million and $1 billion. The option granted to purchase 92,500 shares of Sesen Bio, Inc.'s common stock was equivalent to the 75th percentile of such Radford market analysis.